Find a provider who tests for MRD with clonoSEQ

This page is intended for use by patients and caregivers of the United States.

Please note that Adaptive Biotechnologies provides this listing as a reference tool to help you find a doctor in your area. No fees have been received by or paid to any healthcare providers in exchange for participation. Adaptive Biotechnologies does not verify or monitor the license, credentials, accreditations or qualifications of any doctor listed in this database, and is not responsible for the medical advice of the doctors included in this database. Inclusion does not represent an endorsement, recommendation, assurance or guarantee from Adaptive with respect to medical services or skills of any provider. The healthcare providers listed are those that have authorized their participation on our website and have an existing Laboratory Service Agreement required for ordering tests through Adaptive. If you prefer to seek testing at another institution, they can contact Adaptive at ClinicalServices@adaptivebiotech.com to begin the process of entering into a Laboratory Service Agreement.

Adaptive Biotechnologies is not responsible and shall not be liable to you or others for any decision made or action taken by you in reliance on this information obtained from this database. The selection of a doctor is ultimately your responsibility and is an important decision that should be carefully considered. You are responsible for all communications and interactions with the medical professionals listed.

This site and all content are provided for informational and educational purposes only and does not constitute medical advice or recommendation. Information on the site should not be considered an endorsement, promotion or in any way encouragement for the use of any healthcare provider, procedure or technique, device or product.

TECHNICAL SUMMARY

clonoSEQ^® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.